Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...
Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to ...
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
(Image source: https://gisaid.org/rsv-subtypes-dashboard) ...
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results